| Molecular Formula | C27H34BrN7O3 |
| Molar Mass | 584.51 |
| Density | 1.439±0.06 g/cm3(Predicted) |
| Melting Point | >250℃ |
| Boling Point | 720.0±70.0 °C(Predicted) |
| Solubility | 10 mM in DMSO |
| pKa | 5.24±0.10(Predicted) |
| Storage Condition | 2-8°C(protect from light) |
| 1mg | 5mg | 10mg | |
|---|---|---|---|
| 1 mM | 1.711 ml | 8.554 ml | 17.108 ml |
| 5 mM | 0.342 ml | 1.711 ml | 3.422 ml |
| 10 mM | 0.171 ml | 0.855 ml | 1.711 ml |
| 5 mM | 0.034 ml | 0.171 ml | 0.342 ml |
| use | pabuxiclib impurity 23 is an impurity of pabuxiclib and is an experimental drug developed by Pfizer to treat breast cancer. It is a selective inhibitor of cyclin-dependent kinases CDK4 and CDK6. In addition, it is derived from 6-bromo-2-chloro-8-cyclopentyl-5-methylpyridine-[2,3-d] pyrimidin-7 (8H)-one for the preparation of pyridyl [2,3-d] pyrimidin-7 (8H)-one derivatives as CDK4 and/or CDK6 inhibitors for the treatment of diseases. |